Neuroscience Institute Research and Clinical Trials

Saint Luke’s Marion Bloch Neuroscience Institute features a strong clinical research program to ensure our patients have access to the most innovative and effective treatments. 

Leader in stroke research

Since testing intravenous tPA, the clot-busting drug used to reverse strokes, in the early 1990s, the Saint Luke’s stroke team has been involved in every major stroke intervention research trial. Early participation in trials testing mechanical devices to retrieve clots, led to our extensive experience in clot retrieval and made us leaders in acute stroke treatment.

National Institute of Health StrokeNet

National Institute of Health StrokeNet is consists of 25 regional coordinating centers across the U.S., a national coordinating center at the University of Cincinnati, and a national data management center at the Medical University of South Carolina. The primary goal of this StrokeNet is to maximize efficiencies to develop, promote, and conduct high-quality, multi-site clinical trials focused on key interventions in stroke prevention, treatment, and recovery. 

Saint Luke’s Hospital of Kansas City is a part of the Mid-America Regional Coordinating Center (MARCC) housed at Washington University School of Medicine. Four high-volume stroke centers participate in MARCC including Barnes-Jewish Hospital, St. Louis University Hospital, Saint Luke’s Hospital, and the Order of St. Francis Medical Center. Each of these medical centers is a tertiary care hub with large networks of referring hospitals, and have extensive experience participating in multi-center stroke trials. Drawing from both rural and urban settings, MARCC hospitals admit almost 5,000 stroke patients per year, from diverse geographic locales, racial backgrounds, and socioeconomic strata. Dr. Karin Olds is the Principal Investigator and Debbie Summers is the Research Coordinator for Saint Luke’s. 

Current StrokeNet trials at Saint Luke’s include:

  • MOST study will determine the safety of combining alteplase with argatroban or eptifibatide as compared to alteplase alone. 
  • Sleep SMART is a study to determine whether treatment of obstructive sleep apnea with positive airway pressure after acute ischemic stroke reduces recurrent stroke, myocardial infarction and all-cause mortality 6 months after event

To learn more about our clinical trials, call 816-932-1880.

Other Neuro Institute clinical trials


ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization. Currently enrolling. 

CHARM - Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM). Currently enrolling. 

CV010-031 Axiomatic study will test a new Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Silent Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Non-Hemorrhagic Stroke or Transient Ischemia Attack. Enrollment begins June 2019.

ULS 1820203 Revance Therapeutics, Inc. - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury. Enrollment begins June 2019.

Parkinson’s disease

The INSYTE ACP-NIS-001 (Management of Parkinson's Disease Psychosis in Actual Practice) Study. Currently enrolling.

INSIGHTS M12-927 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) Associated with Advanced Parkinson’s Disease. Currently enrolling.

Multiple sclerosis 

ADS-AMT-MS301 Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment. This is a multicenter, 3-arm, randomized, placebo-controlled, double-blind, parallel-group study of ADS-5102 (amantadine extended release [ER] capsules) in MS patients with walking impairment. ADS-5102 will be administered once daily at bed time. Currently enrolling.

Clinical trials at Saint Luke’s Hospital Midwest Ear Institute

Cochlear Implantation in Adults with Asymmetric Hearing Loss Clinical Trial

Implantation of the HiRes 90K™ Advantage Cochlear Implant with HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults with Partial Deafness

Nucleus® Hybrid™ L24 Implant System: New Enrollment Study

Revised Indications for Cochlear Implant Candidacy for the Adult CMS Population

To learn more about our clinical trials, call 816-932-1880.